Ecaterina Ileana Dumbrava

19PUBLICATIONS
164CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Jan 06, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.

Amber Johnson, Yifei Shen, Xiaofeng Zheng

|Nov 24, 2025
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.

Taiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav

|Aug 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.

Camila Braganca Xavier, Clark R Andersen, JoAnn Lim

|Aug 11, 2025
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.

Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder

Pageof 4